Portal de Periódicos da CAPES

Pathological Outcomes of Patients With Advanced Renal Cell Carcinoma Who Receive Nephrectomy Following Immunotherapy

2023; AlphaMed Press; Volume: 29; Issue: 10 Linguagem: Inglês

10.1093/oncolo/oyad166

1549-490X

Justine Panian, Ava Saidian, Kevin Hakimi, Archana Ajmera, William J. Anderson, Pedro Barata, Stephanie Berg, Sabina Signoretti, Steven L. Chang, Vincent D’Andrea, Daniel J. George, Hannah Dzimitrowicz, Talal El Zarif, Hamid Emamekhoo, Evan Gross, Deepak Kilari, Elaine T. Lam, Isabel Lashgari, Sarah P. Psutka, Grant Rauterkus, Ahmed Shabaik, Bicky Thapa, Luke Wang, Nicole Weise, Kendrick Yim, Tian Zhang, Ithaar Derweesh, Rana R. McKay,

Cancer Genomics and Diagnostics

Abstract Background Even though cytoreductive nephrectomy (CN) was once the standard of care for patients with advanced renal cell carcinoma (RCC), its role in treatment has not been well analyzed or defined in the era of immunotherapy (IO). Materials and Methods This study analyzed pathological outcomes in patients with advanced or metastatic RCC who received IO prior to CN. This was a multi-institutional, retrospective study of patients with advanced or metastatic RCC. Patients were required to receive IO monotherapy or combination therapy prior to radical or partial CN. The primary endpoint assessed surgical pathologic outcomes, including American Joint Committee on Cancer (AJCC) staging and frequency of downstaging, at the time of surgery. Pathologic outcomes were correlated to clinical variables using a Wald-chi squared test from Cox regression in a multi-variable analysis. Secondary outcomes included objective response rate (ORR) defined by response evaluation criteria in solid tumors (RECIST) version 1.1 and progression-free survival (PFS), which were estimated using the Kaplan-Meier method with reported 95% CIs. Results Fifty-two patients from 9 sites were included. Most patients were male (65%), 81% had clear cell histology, 11% had sarcomatoid differentiation. Overall, 44% of patients experienced pathologic downstaging, and 13% had a complete pathologic response. The ORR immediately prior to nephrectomy was stable disease in 29% of patients, partial response in 63%, progressive disease in 4%, and 4% unknown. Median follow-up for the entire cohort was 25.3 months and median PFS was 3.5 years (95% CI, 2.1-4.9). Conclusions IO-based interventions prior to CN in patients with advanced or metastatic RCC demonstrates efficacy, with a small fraction of patients showing a complete response. Additional prospective studies are warranted to investigate the role of CN in the modern IO-era.